Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT103A for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
NCT04561557Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2020
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of equecabtagene autoleucel in Neuromyelitis Optica Spectrum Disorder (NMOSD), myasthenia gravis (MG), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and 5 more (3 arms), sponsored by Tongji Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 2 years. Started Sep 2020; status: recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)myasthenia gravis (MG)chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)idiopathic inflammatory myopathy (IIM)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04561557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561557.